Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026 

SOPHiA GENETICS global leader in AI-driven precision medicine, announced that the Mount Sinai Health System has adopted the AI-powered SOPHiA DDM™ Platform to advance cancer research and enhance genomic testing capabilities. It is one of the leading academic health systems in the United States. 

Ph.D., Director of Molecular Oncology Pathology of the Mount Sinai Health System, Jane Houldsworth, stated this collaboration between Mount Sinai and SOPHiA GENETICS reinforces our commitment to scientific innovation by integrating powerful digital tools into our workflows to support high-quality, data-driven cancer care.  

Leveraging SOPHiA DDM has enabled us to reduce hands-on analysis time and improve our testing turnaround times, enabling our clinicians to provide better patient care. 

According to Towards Healthcare, the Functional Medicine Diagnostic market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 17.09 billion in 2026 to approximately USD 35.61 billion by 2035, representing a compound annual growth rate (CAGR) of 8.5% from 2026 to 2035. Growth is driven by consumers seeking tailored health solutions with the increasing prevalence of chronic diseases to address their unique needs, to enhance diagnostic accuracy, and reduce costs. 

About Mount Sinai 

Mount Sinai is one of the world’s leading centres for cancer research and was recently ranked No. 1 globally among health care institutions in the Nature AI Index, underscoring its leadership in artificial intelligence and data-driven innovation. Honoured to support their teams with an AI-native platform and global network designed to deliver faster results, greater operational efficiency, and deeper genomic understanding to help shape the future of precision oncology. 

This Platform is designed to enable the detection and interpretation of a wide range of complex genomic variants while improving operational efficiency by consolidating critical steps in the analysis pipeline and reducing manual interpretation time. 

It comprises seven hospital campuses, including Mount Sinai Hospital, Mount Sinai Morningside, and Mount Sinai West, along with the Icahn School of Medicine. Also committed to improving health outcomes and expanding access to care for diverse populations.  

A recent report by Towards Healthcare highlights that the Functional Medicine Diagnostic market is witnessing significant growth, driven by the increasing prevalence of chronic diseases and the demand for personalised healthcare solutions, with chronic disease patients and those with digestive, metabolic, immune, and other system problems being the primary segments. 

North America is expected to hold the largest market share due to advanced diagnostic technologies and a large number of healthcare providers. The Asia Pacific region is expected to grow at the highest rate due to the increasing demand for early diagnosis and personalised treatment plans.